AR083835A1 - FACTOR H FOR THE TREATMENT OF AUTOIMMUNE DISEASES OF THE NERVOUS SYSTEM - Google Patents

FACTOR H FOR THE TREATMENT OF AUTOIMMUNE DISEASES OF THE NERVOUS SYSTEM

Info

Publication number
AR083835A1
AR083835A1 ARP110104208A ARP110104208A AR083835A1 AR 083835 A1 AR083835 A1 AR 083835A1 AR P110104208 A ARP110104208 A AR P110104208A AR P110104208 A ARP110104208 A AR P110104208A AR 083835 A1 AR083835 A1 AR 083835A1
Authority
AR
Argentina
Prior art keywords
factor
treatment
nervous system
autoimmune diseases
disease
Prior art date
Application number
ARP110104208A
Other languages
Spanish (es)
Original Assignee
Lab Francais Du Fractionnement
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lab Francais Du Fractionnement filed Critical Lab Francais Du Fractionnement
Publication of AR083835A1 publication Critical patent/AR083835A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1725—Complement proteins, e.g. anaphylatoxin, C3a or C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se divulga el factor H para su uso en el tratamiento de una enfermedad neuromuscular, en particular una enfermedad de la unión neuromuscular como la miastenia, neuropatía periférica, síndrome de Guillan-Barré.Reivindicación 10: Uso de un factor H para la preparación de un medicamento destinado al tratamiento de una enfermedad autoinmune del sistema nervioso.Factor H is disclosed for use in the treatment of a neuromuscular disease, in particular a neuromuscular junction disease such as myasthenia, peripheral neuropathy, Guillan-Barré syndrome. Claim 10: Use of an H factor for the preparation of a medicine intended for the treatment of an autoimmune disease of the nervous system.

ARP110104208A 2010-11-10 2011-11-10 FACTOR H FOR THE TREATMENT OF AUTOIMMUNE DISEASES OF THE NERVOUS SYSTEM AR083835A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1059311A FR2967071A1 (en) 2010-11-10 2010-11-10 H FACTOR FOR THE TREATMENT OF AUTOIMMUNE DISEASES OF THE NERVOUS SYSTEM

Publications (1)

Publication Number Publication Date
AR083835A1 true AR083835A1 (en) 2013-03-27

Family

ID=43608826

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110104208A AR083835A1 (en) 2010-11-10 2011-11-10 FACTOR H FOR THE TREATMENT OF AUTOIMMUNE DISEASES OF THE NERVOUS SYSTEM

Country Status (3)

Country Link
AR (1) AR083835A1 (en)
FR (1) FR2967071A1 (en)
WO (1) WO2012063007A1 (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0742235B2 (en) * 1985-11-08 1995-05-10 三共株式会社 Prophylactic / therapeutic agent for autoimmune diseases
DE122007000007I1 (en) 1986-04-09 2007-05-16 Genzyme Corp Genetically transformed animals secreting a desired protein in milk
US20020082227A1 (en) * 1999-09-30 2002-06-27 Scott Henry Use of oligonucleotides for inhibition of complement activation
FR2894145B1 (en) 2005-12-07 2008-10-17 Lab Francais Du Fractionnement USE OF FACTOR H OF THE COMPLEMENT AS A MEDICINAL PRODUCT
WO2008113589A1 (en) 2007-03-20 2008-09-25 Csl Behring Gmbh Methods for industrial scale production of therapeutic complement factor h preparations from human plasma

Also Published As

Publication number Publication date
FR2967071A1 (en) 2012-05-11
WO2012063007A1 (en) 2012-05-18

Similar Documents

Publication Publication Date Title
GT201200313A (en) 5-FLUORO-1H-REPLACED PIRAZOLOPIRIDINES AND ITS USE
DOP2012000063A (en) (HETEROARILMETIL) THIOHYDANTOINS REPLACED AS ANTICANCER DRUGS
CR20150358A (en) DERIVATIVES OF EXENDINA-4 FUCIONALIZADA
CR20150020A (en) 5-AMINOTETRAHYDROQUINOLIN-2-NEW CARBOXYLIC ACIDS AND THEIR USE
CR20150296A (en) NEWS DERIVED FROM BENCIMIDAZOL AS ANTAGONISTS OF EP4
BR112015010663A8 (en) sustained release oral dosage forms, and use of ruxolitinib or a pharmaceutically acceptable salt thereof
AU2012205878A8 (en) miRNA for treating diseases and conditions associated with neo-angiogenesis
MX353482B (en) METHODS FOR THE TREATMENT OF CANCER and INFLAMMATORY DISEASES USING CEREBLON AS A PREDICTOR.
GT200900230A (en) 4-ARIL-1,4-DIHIDRO-1,6-NAFTIRIDINAMIDES REPLACED AND USE
MX2016008448A (en) Var2csa-drug conjugates.
AU2011274619A8 (en) miRNA and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated BRAF pathway
CL2013000018A1 (en) Compounds derived from indolizine, their preparation procedure; pharmaceutical composition; and use in the treatment of cancer, among others.
BR112012032008A2 (en) s100a4 antibodies and therapeutic uses thereof
DOP2014000114A (en) NOVEL 2HINDAZOLES AS EP2 RECEPTOR ANTAGONISTS
EA201291211A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING HYDROMORPHONE AND NALOXONE
UY35771A (en) TIENOURACIL-CYCLIC CARBOXAMIDES AND ITS USE
CR20110023A (en) NIFURTIMOX FOR THE TREATMENT OF DISEASES CAUSED BY TRICHOMONADIDA
ES2403549R1 (en) Agomelatine co-crystals with co-crystal formers
MX2020006075A (en) Bendamustine pharmaceutical compositions.
UY35037A (en) ANTIPARASITARY COMPOSITION OF SPACIOUS NITAZOXANIDA SPECTRUM, PROBIOTICS AND PREBIOTICS
AR083835A1 (en) FACTOR H FOR THE TREATMENT OF AUTOIMMUNE DISEASES OF THE NERVOUS SYSTEM
EA201590782A1 (en) ОКСИРАНОВЫЕ АМИНЫ
CL2015000310A1 (en) Use of ipidacrine for the treatment of potency disorders, such as disorders of sexual activity; Pharmaceutical formulation containing ipidacrine from 3 to 300 mg.
CU20140058A7 (en) NEW 2H-INDIZOLS AS ANTAGONISTS OF THE EP-2 RECEIVER
HN2010001125A (en) 4- (4-CIANO-2-TIOARIL) DIHYDROPIRIMIDINONES AND ITS USE

Legal Events

Date Code Title Description
FB Suspension of granting procedure